A transdermal patch contains a water-based solution containing electrolytes, vitamins, and at least one permeation enhancer. The water-based solution also acts as an adhesive matrix which binds the patch together. The solution is transferred to the body via an embossed release liner. In use, the permeation of electrolytes into the bloodstream improves the body's ability to manage hydration. The permeation enhancer increases the porosity of the skin in contact with the transdermal patch to make possible the permeation of the solution into the body. Critical proportions of solvent, solutes, and permeation enhancers are disclosed which have been found to make permeation of otherwise non-absorbable ingredients possible.

Disclosed is a method and composition for accelerating wound healing comprising applying a dressing directly on a subject's wound immediately or no later than 72 hours following injury. The dressing reduces or minimizes scarring, prevents or reduces infection, inhibits or reduces internal bleeding, inhibits or reduces external discharge, provides protection from sun and/or UV rays or a combination thereof, thereby accelerating wound healing.

The present invention relates to matrix adhesive patch and its preparation. The present invention specifically relates to an analgesic matrix adhesive patch and its preparation. The present invention more specifically relates to a matrix patch adhesive preparation containing Camphor, Menthol and Methyl salicylate and process for the preparation thereof which delivers predetermined amount of drug continuously through skin and provide the temporary relief of minor aches & pains of muscles & joints associated with; Arthritis, Strains, Bruises & Sprains.

The present invention provides a patch comprising a backing layer and an adhesive agent layer, wherein the adhesive agent layer is non-aqueous, the adhesive agent layer contains nonylic acid vanillylamide, terpene-based resin, rosin-based resin, styrene-isoprene-styrene block copolymer, and liquid paraffin, a mass ratio of a content of the terpene-based resin to a content of the rosin-based resin ((content of the terpene-based resin)/(content of the rosin-based resin)) in the adhesive agent layer is 0.45 to 1.3, and a mass ratio of a content of the styrene-isoprene-styrene block copolymer to a content of the liquid paraffin ((content of the styrene-isoprene-styrene block copolymer)/(content of the liquid paraffin)) in the adhesive agent layer is 0.45 to 1.2.

The present invention provides a rotigotine-containing patch comprising: a backing layer; and an adhesive agent layer, wherein the adhesive agent layer contains rotigotine and/or a pharmaceutically acceptable salt thereof,

the adhesive agent layer further contains a styrene-based thermoplastic elastomer, a petroleum-based resin and/or a terpene-based resin, an aliphatic alcohol, and a cross-linked polyvinylpyrrolidone, and

in the adhesive agent layer, a mass ratio of a content of the rotigotine and/or the pharmaceutically acceptable salt thereof in terms of rotigotine free form and a content of the cross-linked polyvinylpyrrolidone (content of the rotigotine and/or the pharmaceutically acceptable salt thereof in terms of rotigotine free form:content of the cross-linked polyvinylpyrrolidone) is 10:3 to 1:3.

The present invention concerns a method for the production of a transdermal delivery system (TDS) comprising at least one active ingredient, wherein the method comprises temperature-conditioning. Furthermore, the present invention concerns a TDS which can be produced by means of the method in accordance with the invention, as well as the use of the TDS in accordance with the invention.

The present application relates to a transdermal therapeutic system comprising a backing layer impermeable to active substances and a polymer matrix on one side of the backing layer impermeable to active substances, wherein the polymer matrix comprises at least one pharmaceutically active substance, at least one inherently non-self-adhesive polymer and at least one plasticizer, said polymer matrix being free of adhesive polymers. The invention further relates to a method of producing the transdermal therapeutic system and to the use thereof as a drug.

A patch preparation which can produce the effect for preventing any problems due to the misuse of the patch preparation, includes a support and a plaster wherein the plaster includes a) an aliphatic compound with hydrophilic group which is in solid state at room temperature, b) a non-aqueous adhesive, and c) a solvent with a vapor pressure of 1 kPa or more at 20 C.

The present invention relates to transdermal therapeutic systems (TTS) for the transdermal administration of asenapine comprising a self-adhesive layer structure containing a therapeutically effective amount of asenapine, such asenapine TTS for use in a method of treatment, processes of manufacture of such TTS as well as asenapine and transdermal therapeutic systems containing asenapine for use in a method of treatment and to a method of treating a human patient by transdermal administration of asenapine.

A nanoemulsion tape includes an adhesion layer including a nanoemulsion and at least one non-adhesion layer. The nanoemulsion includes at least one oil, at least one oil base surfactant, at least one water base surfactant, water, and either an isolate or distillate. The isolate and the distillate include at least one of a CBD, a THC and a cannabinoid based oil. The nanoemulsion tape may further include a co-surfactant within the nanoemulsion. Further, a method for making the nanoemulsion tape and a method of using the nanoemulsion tape are disclosed.